- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01357369
Study of Drug Concentration of Ondansetron and Cefazolin in Mothers and Neonates
Pharmacokinetics and Placental Transfer of Ondansetron and Cefazolin: A Preliminary Analysis
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
There is very little data on drug metabolism during pregnancy, and how it may differ from the non-pregnant woman. There is even less data on placental transfer of drug to the neonate when medications are given prior to delivery. This study proposes to look at the pharmacokinetics of two drugs (Cefazolin and ondansetron) given routinely to pregnant women who are planning to deliver via cesarean section. The investigators will evaluate the metabolism of both drugs by the pregnant woman, the placental transfer over time, and the subsequent metabolism of the transferred drug in the neonate.
The investigators hope to learn 1) the pk profile of both drugs in pregnancy, and how it differs from the non-pregnant woman, 2) the placental transfer of both drugs, and 3) the profile of neonatal metabolism of the drug that crosses the placental barrier.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
California
-
Stanford, California, Förenta staterna, 94305
- Stanford University School of Medicine
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
Adult participant:
- Age 18-45 years old
- Term pregnancy (37-42 weeks)
- Delivers by planned cesarean section, or unplanned, non-urgent cesarean section.
- Generally healthy
- Able and willing to sign informed consent
Neonatal participant:
- Male of female
- 37-42 weeks gestation
Exclusion Criteria:
- Adult:Medical condition that would effect metabolism of the study drugs
- Known allergy to either study medication
- Use of medications in the last 48 hours that might induce or inhibit metabolism of ondansetron (e.g. barbiturates, fluconazole, erythromycin, etc.)
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
---|---|
Ondansetron/Cefazolin treatment
Pregnant women undergoing uncomplicated cesarean section deliveries who have consented to participate, and will receive Ondansetron and Cefazolin in the course of their clinical care will have PK blood samples drawn.
|
Blood samples will be drawn from the mother, umbilical vein and artery post delivery, and neonate with other clinical labs.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Pharmacokinetics (PK) results for Cefazolin and Ondansetron in maternal blood specimens
Tidsram: 10 hours
|
Plasma concentrations will be reported in mg/L.
Plasma concentration will then be analyzed using nonlinear mixed effects modeling (nonmem) software to determine volume of distribution in L and clearance in L/minute.
|
10 hours
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Identification of placental transfer of studied meds (Cefazolin and Ondansetron)
Tidsram: 1 hr
|
By measuring the PK of the studied drugs in the umbilical cord sample we hope to gain information regarding placental transfer. Plasma concentrations will be reported in mg/L. Plasma concentration will then be analyzed using nonlinear mixed effects modeling (nonmem) software to determine volume of distribution in L and clearance in L/minute. |
1 hr
|
PK results of neonatal blood specimens
Tidsram: 48 h
|
Plasma concentrations will be reported in mg/L.
Plasma concentration will then be analyzed using nonlinear mixed effects modeling (nonmem) software to determine volume of distribution in L and clearance in L/minute.
|
48 h
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: David R. Drover, Stanford University
- Underutredare: Brendan Carvalho, Stanford University
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- SU-02252011-7482
- IRB 20231
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Graviditetskomplikationer
-
Hacettepe UniversityAvslutad
-
IVI BilbaoFundación IVIAvslutadDonator Site ComplicationSpanien
-
Molnlycke Health Care ABAvslutadDonator Site ComplicationFörenta staterna
-
Transwell Biotech Co., Ltd.A2 Healthcare Taiwan CorporationAvslutadDonator Site ComplicationJapan, Taiwan
-
National Taiwan University HospitalAvslutadDonator Site Complication | Muskel; IschemiskTaiwan
-
University Hospital, LinkoepingAvslutadDonator Site ComplicationSverige
-
University Hospitals, LeicesterAvslutadHudtransplantat | Donator Site ComplicationStorbritannien
-
NYU Langone HealthAvslutadDonator Site Complication | Skin Graft DisorderFörenta staterna
-
Clinical Center of VojvodinaRekryteringFrämre korsbandsruptur | Donator Site ComplicationSerbien
-
Oslo University HospitalAvslutadBröstcancer | Tillfredsställelse, personlig | Donator Site Complication